$EBIO gap Pr $2.48 Nasdaq GM Eleven Biotherape
Post# of 98055
Posted On: 07/10/2016 11:27:32 AM
$EBIO gap Pr $2.48
Nasdaq GM
Eleven Biotherapeutics (EBIO)
Stock Skyrocketing on Eye Disease Treatment
Website
Low Float
Shares Outstanding: 19.96M
Float: 5.56M
% Held by Insiders: 12.73%
% Held by Institutions: 73.60%
Shares Short (as of Jun 15, 2016): 1.42M
Short Ratio (as of Jun 15, 2016): 0.33
Short % of Float (as of Jun 15, 2016): 12.78%
Shares Short (prior month): 1.29M
Headlines
Eleven Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its lead product candidate is EBI-005, which has completed Phase III clinical trials for the treatment of patients with dry eye disease and allergic conjunctivitis. The company is also developing EBI-031 that is in preclinical development to treat diabetic macular edema; and a product candidate as an intravitreal injection for the treatment of certain retinal diseases, such as wet age-related macular degeneration. Eleven Biotherapeutics, Inc. has a collaboration and license agreement with ThromboGenics N.V. to identify protein or peptide therapeutics that directly modulate any of a specified set of targets in a novel pathway in retinal disease. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Nasdaq GM
Eleven Biotherapeutics (EBIO)
Stock Skyrocketing on Eye Disease Treatment
Website
Low Float
Shares Outstanding: 19.96M
Float: 5.56M
% Held by Insiders: 12.73%
% Held by Institutions: 73.60%
Shares Short (as of Jun 15, 2016): 1.42M
Short Ratio (as of Jun 15, 2016): 0.33
Short % of Float (as of Jun 15, 2016): 12.78%
Shares Short (prior month): 1.29M
Headlines
Eleven Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its lead product candidate is EBI-005, which has completed Phase III clinical trials for the treatment of patients with dry eye disease and allergic conjunctivitis. The company is also developing EBI-031 that is in preclinical development to treat diabetic macular edema; and a product candidate as an intravitreal injection for the treatment of certain retinal diseases, such as wet age-related macular degeneration. Eleven Biotherapeutics, Inc. has a collaboration and license agreement with ThromboGenics N.V. to identify protein or peptide therapeutics that directly modulate any of a specified set of targets in a novel pathway in retinal disease. The company was founded in 2008 and is based in Cambridge, Massachusetts.
(0)
(0)Scroll down for more posts ▼